

Spark NIR™ 685 anti-human CD19

Catalog # / Size: 2111350 / 100 tests
2111345 / 25 tests

Clone: HIB19

Isotype: Mouse IgG1, κ

Immunogen: CX3CR1-EGFP fusion protein


Reactivity: Human, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with Spark NIR™ 685 under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

Workshop Number: V CD19.11

Concentration: Lot-specific




Human peripheral blood lymphocytes were stained with CD19 (clone HIB19) Spark NIR™ 685 (filled histogram). Open histogram represents unstained cells.

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



* Spark NIR™ 685 has a maximum excitation of 665 nm and a maximum emission of 685 nm.

Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections⁸ and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

**Application
References:**

1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
 2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
 3. Bradbury L, et al. 1993. *J. Immunol.* 151:2915.
 4. Joseph A, et al. 2010. *J. Virol.* 84:6645. [PubMed](#)
 5. Wang X, et al. 2010. *Haematologica.* 95:884. (FC) [PubMed](#)
 6. Walker JD, et al. 2009. *J. Immunol.* 182:1548. (Block) [PubMed](#)
 7. Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
 8. Hansen A, et al. 2002. *Arthritis Rheum.* 46:2160. (IHC)
 9. Stoeckius M, et al. 2017. *Nat. Methods.* 14:865. (PG)
 10. Peterson VM, et al. 2017. *Nat. Biotechnol.* 35:936. (PG)
-

Description:

CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

**Antigen
References:**

1. Tedder T, et al. 1994. *Immunol. Today* 15:437.
2. Bradbury L, et al. 1993. *J. Immunol.* 151:2915.